Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Bial - Portela C S.A. clinical trials
Part of BIAL Holding, S.A., which holds 100% as of 2022-12-31. Source
The registry lists 139 studies whose lead sponsor is Bial - Portela C S.A. or one of 1 company grouped under it. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 11, 2026.
Keep track of what changes. Save the Bial - Portela C S.A. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Bial - Portela C S.A..
- Bial - Portela C S.A.136 studiesSame company
Something wrong?
- Bial R&D Investments, S.A.3 studies →Subsidiary
Something wrong?
Focus areas
Conditions Bial - Portela C S.A. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 139. Browse all 139 →
- SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world TreatmentRecruitingNCT07145190
- Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE StudyNo longer availableNCT07522606
Sponsor listed in the registry: Bial R&D Investments, S.A.
- REal-life ON PARKinson's - ITaly (REONPARK-IT)Active, not recruitingNCT07403799
- Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PDActive, not recruitingNCT05819359Phase 2
Sponsor listed in the registry: Bial R&D Investments, S.A.
- Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and FurosemideCompletedNCT07173738Phase 1
- Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156CompletedNCT05220072Phase 1
Sponsor listed in the registry: Bial R&D Investments, S.A.
- Anti-epileptogenic Effects of Eslicarbazepine AcetateCompletedNCT06597084Phase 2
- A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and TopiramateCompletedNCT02283814Phase 1
- Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac RepolarizationCompletedNCT02283788Phase 1
- Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepineCompletedNCT02281591Phase 1
- A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy VolunteersCompletedNCT01879345Phase 1
- The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of DigoxinCompletedNCT02172742Phase 1
- Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy VolunteersCompletedNCT01679002Phase 1
- OpiCapone Effect on Motor Fluctuations and pAiNCompletedNCT04986982Phase 4
- Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial EpilepsyCompletedNCT00957047Phase 3
- OpicApone Sleep dISorderCompletedNCT04986995Phase 4
- eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.CompletedNCT04990284Phase 4
- Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial SeizuresCompletedNCT00957684Phase 3
- Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy VolunteersCompletedNCT02305277Phase 1
- Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)CompletedNCT04978597Phase 3
- Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)CompletedNCT04316143Phase 2
- Safety and Efficacy of BIA 5-1058 in PAHCompletedNCT06009185Phase 2
- Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's DiseaseCompletedNCT03959540
- Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of SildenafilCompletedNCT04994860Phase 1
- Effect of BIA 5-1058 400 mg on Warfarin PharmacokineticsCompletedNCT04994119Phase 1
- Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058TerminatedNCT04991194Phase 1
- Absorption, Distribution, Metabolism and Excretion of BIA 5-1058CompletedNCT04991181Phase 1
- Effect of Food on BIA 5-1058CompletedNCT04991155Phase 1
- Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of BosentanCompletedNCT04991207Phase 1
- Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial SeizuresCompletedNCT00988429Phase 3
- Absorption, Distribution, Metabolism and Excretion of [14C] Labelled BIA 5-1058CompletedNCT04069130Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058CompletedNCT03708146Phase 1
- Relative Bioavailability and Bioequivalence of OpicaponeCompletedNCT03820037Phase 1
- Effect of BIA 5 1058 on Cardiac RepolarizationCompletedNCT03489005Phase 1
- Effect of BIA 5-1058 on the Steady State Pharmacokinetics of TreprostinilCompletedNCT04675944Phase 1
- Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)CompletedNCT04265027Phase 1
- Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in ChildrenCompletedNCT00988156Phase 3
- Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset SeizuresCompletedNCT02484001Phase 3
- Bioavailability and Bioequivalence Study of Two Different Sources of OpicaponeCompletedNCT03116295Phase 1
- Efficacy and Safety of Opicapone in Clinical PracticeCompletedNCT02847442Phase 4
- Pharmacokinetics, Efficacy and Tolerability of BIA 2-093CompletedNCT02170064Phase 2
- Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067CompletedNCT03119194Phase 1
- Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of WarfarinCompletedNCT02779348Phase 1
- A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093CompletedNCT02170077Phase 2
- Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly PatientsCompletedNCT01422720Phase 3
- Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its MetabolitesCompletedNCT02172755Phase 1
- The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093CompletedNCT02170649Phase 1
- Effect of Food on OpicaponeCompletedNCT03116308Phase 1
- Bioequivalence of Two Different Sources of Eslicarbazepine AcetateCompletedNCT03116321Phase 1
- Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" PhenomenonCompletedNCT03103399Phase 2